Cencora Inc. Q4 2025 Earnings Recap

COR Q4 2025 November 6, 2025

Get alerts when COR reports next quarter

Cencora reported robust fiscal 2025 results, with adjusted operating income and diluted EPS growth of 16%, driven by strategic investments in specialty services and strong pharmaceutical utilization trends. The company has raised its long-term guidance for adjusted operating income and EPS growth amid a positive market outlook.

Earnings Per Share Beat

$3.84 vs $3.79 est.

+1.3% surprise

Revenue Beat

83728554000 vs 83458234370 est.

+0.3% surprise

Market Reaction

1-Day +0.13%

5-Day +1.45%

30-Day -6.37%

See COR alongside your other holdings

Add to your portfolio — free

Key Takeaways

Adjusted operating income and diluted EPS rose by 16%, reflecting effective strategic positioning in the specialty market.
Cencora is prioritizing growth-oriented investments, including a $1 billion commitment to enhance its distribution network through 2030.
The company is strategically reviewing non-core businesses, such as the Animal Health segment, to streamline focus and enhance operational alignment.
Long-term guidance has been updated to reflect expected adjusted operating income growth of 6% to 9% and adjusted EPS growth of 9% to 13%.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit COR on AllInvestView.

Next Q1 2026